Sequelograph

A real event, read carefully. Then a fiction that does not pretend to be the news.

The record, 25 Mar 2026

Beam reports protein gains in 29-patient base-editing trial

On March 25, BioPharma Dive reported updated data from Beam Therapeutics' ongoing Phase 1/2 trial of BEAM-302, a base-editing therapy for alpha-1 antitrypsin deficiency that changes single DNA letters to restore correctly folded protein. Across three dose groups totaling 29 patients followed for about one to 12 months, all groups produced functional protein above a level believed to be protective, and misfolded protein fell by over 80% on average; two patients showed elevated liver enzymes but had no symptoms and needed no treatment. The data are company-reported, early-phase results in a small group, and Beam said it would advance a single 60 mg dose into an expanded trial and pursue an accelerated approval path.

Read the source at BioPharma Dive

The record ends here. Everything below this line is invented.

What if one fixed DNA letter could guard both the lungs and the liver?

Part one

The Honest Breath

The note broke in the middle of her solo phrase, the way ice gives on a pond – a clean high G that thinned, wavered, and went to air. Clara felt it go and kept her face still, the way you do when forty people are breathing with you and the silence after your note belongs to everyone. The director's hand paused. Her husband Otto, two rows back in the basses, turned one page too loudly, covering for her the way he'd covered for her all spring.

It was March, six weeks to the spring concert, and Clara had sung alto in the riverside choir for eleven years. The solo in the spring piece was eight bars she had waited a decade to earn – a slow climb ending on the G she had just lost. She marked her score where the breath had failed, then quietly penciled in a breath mark two beats early, where the phrase didn't want one. A cheat, small and invisible. Her third this month.

Nobody in the choir knew why her breath was leaving. Three years ago a blood test had given it a name she still said carefully, syllable by syllable: alpha-1 antitrypsin deficiency. Her body's copy of one gene carried a wrong letter, so her liver built a protective protein folded into the wrong shape. The misfolded protein couldn't guard her lungs, and the pile of it clogged the liver that made it. One mistake, two organs. She had read that sentence eleven times the night she got the diagnosis, because it explained both her breath and her tired yellow afternoons.

What she hadn't told the choir, or Otto's mother, or anyone past Otto, was the appointment she'd kept in February. The therapy was new – newly approved, after years of trials – and it worked the way only the new medicine worked: a single infusion that found the gene in her liver cells and swapped the wrong DNA letter for the right one. One letter. Her liver would fold the protein correctly from then on. She had signed the papers with her choir pencil.

The first blood test after the infusion came back the week the solo rehearsals began, and the numbers were the kind you frame. Her protective protein had climbed past the line the clinic called protective – the level where lungs and liver were considered guarded. The misfolded kind had fallen by four-fifths. The nurse used the word beautiful. Clara carried the printout in her music folder for a week, showing no one, reading it the way she'd once read love letters.

But the G kept breaking.

That was the wrongness she couldn't fit into any envelope. The blood said guarded. The breath said otherwise. She did what singers do: she worked harder. She walked the river stairs morning and night. She slept with the window open. She took the breath mark out, put it back, took it out again. The note broke on schedule, like a guest who no longer knocked.

Halfway through April she brought the printout and the problem to the clinic together, and the doctor – a young woman with choir-concert posture – laid them side by side and said the sentence that rearranged the furniture of Clara's spring.

"The shield is back," she said. "The dents stay."

She drew it simply: the protein guarded against new damage from here forward, but the years without it had thinned the walls of Clara's smallest airways, and thin walls didn't rethicken. The infusion had stopped a fire. It hadn't rebuilt the rooms. Clara's breath would hold where it was – likely for years, maybe decades – but the G she remembered belonged to lungs from before the diagnosis, and no blood test could buy those back.

Clara sat with that a long moment, and then she laughed, once, because the alternative was crying in a paper gown. All spring she had believed the blood and the breath were the same promise. They were two promises. One had been kept.

She went home and did the unthinkable: she kept the early breath mark. Then she did the harder thing – she told the director why, in plain words, in the empty hall, and asked for the arrangement to give her the breath honestly instead of stealing it. The director listened, moved one rest, and the phrase opened like a door. At the next rehearsal Clara sang the climb, took the honest breath, and landed the G – shorter than written, true as a bell. Otto's page-turn, when it came, was just a page-turn.

The concert was Sunday. At Saturday's dress rehearsal she sang the solo clean, took her honest breath, and felt the hall lean in.

Six weeks, the doctor had said, for the numbers. Decades, for what the numbers guarded. Clara stood at her kitchen window turning it over: one corrected DNA letter can restore a protein that guards both lungs and liver. Fourteen words that had traveled from a trial of twenty-nine strangers into her blood. Somewhere behind her, the kettle sang its own small note and went quiet, and she understood that her spring had never been about getting her old breath back. It was about learning, measure by measure, what the new one could carry.

Afterward, folding chairs with the others, she heard it: from the tenor risers, a cough pressed small and private, and young Emil, twenty-four, new, bright-voiced, folding his part to hide the breath marks he had penciled in the margins, three this month, small and invisible.

He looked up and found her watching. "How did you get your breath back?" he asked.

What’s real

  • BEAM-302 edits single DNA letters in a trial.
  • All dose groups passed the protective protein level.
  • Two patients had symptom-free liver enzyme rises.

What’s invented

  • Clara, Otto, and the choir are fictional.
  • The approved therapy program is speculative.
  • Her concert and scan results are invented.

Part two: The Tenor's Turn

A breathless tenor asks Clara how she got her voice back, and answering will cost her the privacy she sang to protect.

Part two isn’t on sale yet. Check back soon.

Filed under medicine, base editing, rare disease.

More records

How it works

Each record starts with one real science event, with a link to where it was reported.

A short story then asks what happens next. Part one is free to read.

Part two costs a few dollars, paid once. You keep it.